Wave Life Sciences Ltd. announced that on September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development, resigned effective as of October 14, 2022 to pursue another opportunity. Dr. Panzara's departure was not the result of any disagreement regarding any matter relating to the Company's operations, policies or practices and he has agreed to serve as a consultant to the Company following his resignation to assist with a smooth transition of his duties. Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheungwill be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.

Ms. Li-Kwai-Cheung ascends to this role with extensive global drug development and global program leadership experience in neurology and rare diseases, including deep expertise in regulatory affairs, compliance, quality and policy. Immediately prior to joining Wave, she was life cycle leader for tominersen at Roche, guiding the Phase 3 program and other late-stage development activities, including responsibility for commercial activity, reimbursement, medical affairs, development and manufacturing and supply. In addition, she led the filing and development team at Roche through the global launch of Ocrevus for multiple sclerosis.